Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Other Non-Current Assets (2019 - 2025)

Lyell Immunopharma (LYEL) has disclosed Other Non-Current Assets for 7 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 6.21% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 6.21% year-over-year, with the annual reading at $1.6 million for FY2025, 6.21% down from the prior year.
  • Other Non-Current Assets hit $1.6 million in Q4 2025 for Lyell Immunopharma, down from $2.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $3.2 million in Q1 2025 to a low of $279000.0 in Q1 2022.
  • Historically, Other Non-Current Assets has averaged $827000.0 across 5 years, with a median of $287500.0 in 2024.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 40.13% in 2022 and later skyrocketed 1025.17% in 2025.
  • Year by year, Other Non-Current Assets stood at $466000.0 in 2021, then plummeted by 39.91% to $280000.0 in 2022, then rose by 1.43% to $284000.0 in 2023, then soared by 495.07% to $1.7 million in 2024, then fell by 6.21% to $1.6 million in 2025.
  • Business Quant data shows Other Non-Current Assets for LYEL at $1.6 million in Q4 2025, $2.5 million in Q3 2025, and $2.5 million in Q2 2025.